Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Drug Discovery
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 289216
Compound shall mean the chemical having the structure of (±)-(S)-4-{4-[(4-Chlorophenyl)(2-pyridyl)methoxy]piperidino}butyric acid monobenzenesulfonate, also known as bepotastine besilate and TAU-284 and any enantiomers, salt forms and any other alternate or derivative forms of the chemical compound.
'Product' shall mean any ophthalmic pharmaceutical preparation containing the Compound as an active pharmaceutical ingredient (API), whether alone or in combination with other API s, for use in the treatment of allergies ;md related symptoms, in any and all delivery forms and presentations, other than transdermal, oral, or parenteral dosage forms.
The patents relate to Piperdine and Piperazine Derivatives.
IPSCIO Record ID: 367335
Licensor is the owner or the exclusive licensee under an Agreement of certain rights, information and materials related to the Compound and/or the Product and its respective uses and commercialization in certain territory.
Compound shall mean the chemical having the structure of (+)-(S)-4-{4-[(4-Chlorophenyl)(2-pyridyl)methoxy ]piperidino} butyric acid monobenzenesulfonate (also known as bepotastine hesitate and TAU-284) and any Alternate Compounds.
Product shall mean any pharmaceutical product, in any nasal,including but not limited to intranasal, dosage forms, including any applicable delivery devices, containing the Compound as an API.
Licensor Trademark shall mean any trademark selected by the JSC, owned and/or controlled by Licensor to be registered by Licensor in the Territory for the exclusive use by Licensee in the Territory in the commercialization of the Product.
Bepotastine is an investigational product for the treatment of allergy symptoms.
Allergic rhinitis is inflammation of the inside of the nose caused by an allergen, such as pollen, dust, mould or flakes of skin from certain animals.
IPSCIO Record ID: 239019
The Licensee intends to develop, manufacture, use, obtain governmental approval for, offer to sell, sell, and commercialize the Product in certain countries or areas of North America.
Compound shall mean the substance 3- (4-Allyl-1-piperazinyl)-2, 2-dimethylpropylmethyl 1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridine dicarboxylate dihydrochloride, (also known as iganidipine dihydrochloride and KS-288), including without limitation, all enantiomers and any other alternate or derivative forms.
Product shall mean any ophthalmic pharmaceutical product containing the Compound as an active pharmaceutical ingredient (API), whether alone or in combination with other API s, in any and all delivery forms and presentations other than transdermal, oral, or parenteral dosage forms.
